In This Article:
GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the Marketing Authorisation Application, MAA, for the use of depemokimab in two indications. The submitted indications are for add-on maintenance treatment of asthma in adult and adolescent patients aged 12 years and older with type 2 inflammation characterised by an eosinophilic phenotype who are inadequately controlled on medium to high dose corticosteroids plus another asthma controller and also as an add-on treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps.
Invest with Confidence:
-
Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
-
Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GSK:
-
GSK announces EMA to review the regulatory application of Shingrix
-
GSK, Oxford to establish GSK-Oxford Cancer Immuno-Prevention Programme
-
GSK Pharma call volume above normal and directionally bullish
-
GSK’s Jemperli Gains Expanded EU Approval for Endometrial Cancer
-
GSK announces expanded EU approval in endometrial cancer for Jemperli combo